Free Trial
NASDAQ:VIRX

Viracta Therapeutics (VIRX) Stock Price, News & Analysis

Viracta Therapeutics logo
$0.0098 0.00 (0.00%)
As of 07/25/2025

About Viracta Therapeutics Stock (NASDAQ:VIRX)

Key Stats

Today's Range
$0.0098
$0.0098
50-Day Range
$0.0096
$0.0187
52-Week Range
$0.01
$0.56
Volume
N/A
Average Volume
1.11 million shs
Market Capitalization
$388.70 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.75
Consensus Rating
Hold

Company Overview

Viracta Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
51st Percentile Overall Score

VIRX MarketRank™: 

Viracta Therapeutics scored higher than 51% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Viracta Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Viracta Therapeutics has received no research coverage in the past 90 days.

  • Read more about Viracta Therapeutics' stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Viracta Therapeutics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Viracta Therapeutics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Viracta Therapeutics has a P/B Ratio of 0.03. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Viracta Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    0.02% of the float of Viracta Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Viracta Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Viracta Therapeutics has recently decreased by 41.73%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Viracta Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Viracta Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.02% of the float of Viracta Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Viracta Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Viracta Therapeutics has recently decreased by 41.73%, indicating that investor sentiment is improving significantly.
    • Insider Buying vs. Insider Selling

      In the past three months, Viracta Therapeutics insiders have not sold or bought any company stock.

    • Percentage Held by Insiders

      10.69% of the stock of Viracta Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

    • Percentage Held by Institutions

      Only 31.37% of the stock of Viracta Therapeutics is held by institutions.

    • Read more about Viracta Therapeutics' insider trading history.
    Receive VIRX Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for Viracta Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

    VIRX Stock News Headlines

    The $7 company helping Nvidia build the world’s first trillion-dollar robot …
    Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profitable trends in tech … well ahead of Wall Street. Like when he called Nvidia at a mere 80 cents a share. Or Bitcoin when it was trading for just $300. Throughout his illustrious career … Michael has given his followers almost 150 different chances to register triple-digit gains.
    Viracta Therapeutics terminates employees, to wind down operations
    Viracta Therapeutics Announces Wind Down of Operations
    See More Headlines

    VIRX Stock Analysis - Frequently Asked Questions

    Viracta Therapeutics' stock was trading at $0.1609 on January 1st, 2025. Since then, VIRX stock has decreased by 93.9% and is now trading at $0.0098.

    Viracta Therapeutics, Inc. (NASDAQ:VIRX) issued its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.40) EPS for the quarter, missing analysts' consensus estimates of ($0.31) by $0.09.

    Shares of VIRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

    Based on aggregate information from My MarketBeat watchlists, some other companies that Viracta Therapeutics investors own include Meta Platforms (META), Intel (INTC), Applied Genetic Technologies (AGTC), C3.ai (AI), Advanced Micro Devices (AMD) and NVIDIA (NVDA).

    Company Calendar

    Last Earnings
    11/10/2021
    Today
    7/27/2025
    Next Earnings (Estimated)
    8/12/2025
    Fiscal Year End
    12/31/2025

    Industry, Sector and Symbol

    Stock Exchange
    NASDAQ
    Sector
    Medical
    Industry
    Pharmaceutical preparations
    Sub-Industry
    Pharmaceutical Products
    Current Symbol
    NASDAQ:VIRX
    CIK
    1061027
    Employees
    20
    Year Founded
    N/A

    Price Target and Rating

    High Price Target
    $3.00
    Low Price Target
    $0.25
    Potential Upside/Downside
    +17,793.7%
    Consensus Rating
    Hold
    Rating Score (0-4)
    2.33
    Research Coverage
    3 Analysts

    Profitability

    EPS (Trailing Twelve Months)
    ($1.10)
    Trailing P/E Ratio
    N/A
    Forward P/E Ratio
    N/A
    P/E Growth
    N/A
    Net Income
    -$51.06 million
    Net Margins
    N/A
    Pretax Margin
    N/A
    Return on Equity
    -1,899.61%
    Return on Assets
    -114.21%

    Debt

    Debt-to-Equity Ratio
    N/A
    Current Ratio
    0.76
    Quick Ratio
    0.76

    Sales & Book Value

    Annual Sales
    N/A
    Price / Sales
    N/A
    Cash Flow
    N/A
    Price / Cash Flow
    N/A
    Book Value
    $0.33 per share
    Price / Book
    0.03

    Miscellaneous

    Outstanding Shares
    39,744,000
    Free Float
    35,495,000
    Market Cap
    $388.70 thousand
    Optionable
    No Data
    Beta
    1.06
    7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

    Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

    Get This Free Report

    This page (NASDAQ:VIRX) was last updated on 7/27/2025 by MarketBeat.com Staff
    From Our Partners